Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Accounting Officer | February 02, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 299,390 |
Ending reported balance
After 2026-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-02 · Sale · Disposed 36,142 · Balance 312,772 F1: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. Row 2 · 2026-02-02 · Sale · Disposed 13,382 · Balance 299,390 F1: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.
F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 13,382 | $1.39 | $18,600.98 |
DisclosureSEC source: 0002007730-26-000002 · primarydocument.xml · nonDerivative · entry 2 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 299,390 F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 36,142 | $1.39 | $50,237.38 |
DisclosureSEC source: 0002007730-26-000002 · primarydocument.xml · nonDerivative · entry 1 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,772 F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:37 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 119,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0002007730-26-000001 · primarydocument.xml · derivative · entry 2 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires 2036-01-30 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:37 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002007730-26-000001 · primarydocument.xml · nonDerivative · entry 1 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,914 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:13 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Exercise / conversionStock Option (Right to buy) · Derivative | 15,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001562180-25-004717 · primarydocument.xml · derivative · entry 3 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,000 Underlying: Common Stock · 15,000 shares Expires 2034-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This stock option exercise was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024. F4 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:13 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 15,000 | $4.01 | $60,150.00 |
DisclosureSEC source: 0001562180-25-004717 · primarydocument.xml · nonDerivative · entry 2 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,914 F2 · shares: This sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024. F3 · price: The shares were sold at prices ranging from $4.00 to $4.03 and the price reported reflects the weighted average sale price. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:13 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Exercise / conversionCommon Stock | 15,000 | $1.68 | $25,200.00 |
DisclosureSEC source: 0001562180-25-004717 · primarydocument.xml · nonDerivative · entry 1 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This stock option exercise was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:35 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 13,334 | $3.53 | $47,069.02 |
DisclosureSEC source: 0001562180-25-004491 · primarydocument.xml · nonDerivative · entry 1 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,914 F1 · shares: This sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the Reporting Person on December 12, 2024. F2 · price: The shares were sold at prices ranging from $3.50 to $3.60 and the price reported reflects the weighted average sale price. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:52 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 30,202 | $2.10 | $63,424.20 |
DisclosureSEC source: 0001562180-25-000915 · primarydocument.xml · nonDerivative · entry 2 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,248 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. F4 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2023. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:52 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 128,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001562180-25-000915 · primarydocument.xml · derivative · entry 3 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 128,000 shares Expires 2035-01-31 F5 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:52 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000915 · primarydocument.xml · nonDerivative · entry 1 Malabre Richard C · CIK 0002007730 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,450 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on December 31, 2024 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 336,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001562180-24-000980 · primarydocument.xml · derivative · entry 2 Malabre Richard C · CIK 0002007730 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,000 Underlying: Common Stock · 336,000 shares Expires 2034-01-31 F2 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 223,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000980 · primarydocument.xml · nonDerivative · entry 1 Malabre Richard C · CIK 0002007730 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,950 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.